Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Amdocs Limited is a software-infrastructure business based in the US. Amdocs shares (DOX) are listed on the NASDAQ and all prices are listed in US Dollars. Amdocs employs 27,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$76.84|
|52-week range||$53.93 - $81.64|
|50-day moving average||$77.26|
|200-day moving average||$77.60|
|Wall St. target price||$87.75|
|Dividend yield||$1.375 (1.79%)|
|Earnings per share (TTM)||$5.35|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-1.02%|
|1 month (2021-08-26)||0.76%|
|3 months (2021-06-25)||-2.55%|
|6 months (2021-03-26)||-6.48%|
|1 year (2020-09-25)||33.59%|
|2 years (2019-09-26)||15.55%|
|3 years (2018-09-26)||16.74%|
|5 years (2016-09-26)||32.35%|
Valuing Amdocs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amdocs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amdocs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Amdocs shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amdocs's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1494. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amdocs's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amdocs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $802 million.
The EBITDA is a measure of a Amdocs's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$4.3 billion|
|Operating margin TTM||13.9%|
|Gross profit TTM||$1.4 billion|
|Return on assets TTM||5.71%|
|Return on equity TTM||19.1%|
|Market capitalisation||$9.7 billion|
TTM: trailing 12 months
There are currently 2.8 million Amdocs shares held short by investors – that's known as Amdocs's "short interest". This figure is 2.6% up from 2.8 million last month.
There are a few different ways that this level of interest in shorting Amdocs shares can be evaluated.
Amdocs's "short interest ratio" (SIR) is the quantity of Amdocs shares currently shorted divided by the average quantity of Amdocs shares traded daily (recently around 482975.59322034). Amdocs's SIR currently stands at 5.9. In other words for every 100,000 Amdocs shares traded daily on the market, roughly 5900 shares are currently held short.
However Amdocs's short interest can also be evaluated against the total number of Amdocs shares, or, against the total number of tradable Amdocs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amdocs's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Amdocs shares in existence, roughly 20 shares are currently held short) or 0.0229% of the tradable shares (for every 100,000 tradable Amdocs shares, roughly 23 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Amdocs.
Find out more about how you can short Amdocs stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amdocs.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 20.97
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amdocs's overall score of 20.97 (as at 12/31/2018) is pretty good – landing it in it in the 21st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Amdocs is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 6.71/100
Amdocs's environmental score of 6.71 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Amdocs is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.33/100
Amdocs's social score of 15.33 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Amdocs is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.44/100
Amdocs's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Amdocs is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Amdocs scored a 1 out of 5 for controversy – the highest score possible, reflecting that Amdocs has managed to keep its nose clean.
|Total ESG score||20.97|
|Total ESG percentile||20.5|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||1|
Dividend payout ratio: 28.9% of net profits
Recently Amdocs has paid out, on average, around 28.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.87% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amdocs shareholders could enjoy a 1.87% return on their shares, in the form of dividend payments. In Amdocs's case, that would currently equate to about $1.375 per share.
While Amdocs's payout ratio might seem fairly standard, it's worth remembering that Amdocs may be investing much of the rest of its net profits in future growth.
Amdocs's most recent dividend payout was on 28 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 28 September 2021 (the "ex-dividend date").
Over the last 12 months, Amdocs's shares have ranged in value from as little as $53.9349 up to $81.6396. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amdocs's is 0.786. This would suggest that Amdocs's shares are less volatile than average (for this exchange).
Amdocs Limited, through its subsidiaries, provides software and services to the communications, cable and satellite, entertainment, and media industry service providers worldwide. The company offers a line of services designed for various stages of a service provider's lifecycle, including planning, delivery, implementation, and ongoing support and operations, such as end-to-end systems integration, managed, testing, cloud, digital business operations, and consulting services that addresses service providers business imperatives, including consumer experience and monetization, media and digital services, enterprise and connected society, open cloud networks, new domains and disruptions, and services and hybrid operations. It also provides revenue guard services designed to detect and resolve revenue leakage, fraud, and cyber fraud; and the BriteBill, a multi-channel bill presentment platform. In addition, the company offers advertising and media services for media publishers, TV networks, video streaming providers, advertising agencies, and service providers. Amdocs Limited was founded in 1988 and is headquartered in Chesterfield, Missouri. .
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.